MitoRx’s pipeline is built around our lead asset MTRX31

A first-in-class small molecule being developed as a monotherapy for high-risk obesity by restoring healthy mitochondrial metabolism, with potential to be used as a first-line therapy in certain patient populations.

Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industry-standard preclinical model of obesity. MTRX31-driven weight-loss does not involve lean mass loss.

Currently being advanced for subcutaneous administration, MitoRx Therapeutics is also developing an orally optimized derivative of MTRX31.